Abstract
Background Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) share a complex relationship with gender, risk, and co-morbidities. There is paucity of data on the gender-based differences in the prevalence of risks and co-morbidities in AECOPD in Nepal.
Methods We performed a retrospective cross-sectional study where data were collected from medical records of adult patients (age >40 years), hospitalized with clinical diagnosis of AECOPD in a tertiary level University hospital in eastern Nepal from April 15, 2014 to October 15, 2014 were included. Data analysis was performed by using SPSS software (Version 26.0, 2020; SPSS Inc., Chicago, IL).
Results Of the 256 patients with the primary diagnosis of AECOPD, mean age was 69 years and 65.63% (n=168) of hospitalizations were female population. Compared to males, 64.32 % (n=137) of active smokers were females p= 0.299, 76.19% (n=32) of diabetics were females p= 0.155, 72.86% (n=51) of hypertensive were females, p= 0.143, 50% (n= 6) of underlying Atrial fibrillation were in females p= 0.350, 57.50% (n= 23) of anemics were females p= 0.278, 100% (n= 3) of asthmatics were females p= 0.553, 44.44% (n= 8) of Pulmonary tuberculosis were in females p= 0.070, and 78.76% (n= 89) of indoor air pollution exposure was in females p <0.001.
Conclusion Females have higher association to indoor air pollution exposure compared to male and this association was found to be statistically significant. The higher incidence of AECOPD hospitalization in females can be explained by these findings. We need larger studies to validate these findings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
not registered
Funding Statement
NONE
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance from Institutional Review Committee, B. P. Koirala Institute of Health Sciences Dharan, Nepal has been granted on April 9, 2015 Our study was approved from the IRC. The consent was waived based on the nature and quality of the study as follows. The study is a retrospective chart review of hospitalizations for COPD exacerbation. The research fits criteria of consent waiver from IRC of BPKIHS due to: 1. The research involves the collection of limited de-identified data from medical charts of BPKIHS retrospectively AND 2. The data is recorded by the investigator in an anonymous manner such that subjects cannot be identified directly or through identifiers linked to the subject. Approved by : Head of Department of Internal Medicine and Chair of Pulmonology, Critical Care and Sleep medicine: Prof. Dr. Narendra Bhatta
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
nischitbaral{at}gmail.com
nbnraj{at}hotmail.com
Premrajparajuli{at}gmail.com
bellla11{at}msu.edu
bidhanraj.paudel{at}gmail.com
anish_paudel{at}outlook.com
neerjan.adh{at}gmail.com
mepunkazz{at}gmail.com
bhattanarendra{at}hotmail.com
FUNDING: NONE
DISCLOSURE: All the authors have no relationships relevant to the contents of this paper to disclose
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.